1-3 of 3
Emily F. Mason
Close
Sort by
Journal Articles

A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML

Clinical Trials & Observations
Emily F. Mason, Olga Pozdnyakova, Mikhail Roshal, Amir T. Fathi, Eytan M. Stein, P. Brent Ferrell, Aaron C. Shaver, Mark Frattini, Hongfang Wang, Lei Hua, Jimmy Mu, Sung Choe, Rengyi Xu, Caroline Almon, Michael Cooper, Richard M. Stone, Robert P. Hasserjian, Michael R. Savona
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2279–2283.
https://doi.org/10.1182/bloodadvances.2020003685
Published: 2021
Includes: Supplemental data
Journal Articles

Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome

Emily F. Mason, Robert P. Hasserjian, Nidhi Aggarwal, Adam C. Seegmiller, Olga Pozdnyakova
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3322–3332.
https://doi.org/10.1182/bloodadvances.2019000328
Published: 2019
Includes: Supplemental data
Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Clinical Trials & Observations
Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1540–1545.
https://doi.org/10.1182/bloodadvances.2019000090
Published: 2019